Startseite>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>Mobocertinib succinate

Mobocertinib succinate

Katalog-Nr.GC62160

Mobocertinib (TAK-788) Succinat ist ein oral aktiver und irreversibler EGFR/HER2-Hemmer. Mobocertinibsuccinat hemmt wirksam onkogene Varianten, die aktivierende EGFRex20ins-Mutationen mit SelektivitÄt gegenÜber Wildtyp-EGFR enthalten. Mobocertinibsuccinat kann in der NSCLC-Forschung eingesetzt werden.

Products are for research use only. Not for human use. We do not sell to patients.

Mobocertinib succinate Chemische Struktur

Cas No.: 2389149-74-8

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
40,00 $
Auf Lager
10 mg
36,00 $
Auf Lager
25 mg
68,00 $
Auf Lager
50 mg
117,00 $
Auf Lager
100 mg
189,00 $
Auf Lager
500 mg
702,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Mobocertinib succinate (TAK-788 succinate) is a potent and orally active inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, with selectivity over WT EGFR. Antitumor activity[1][2].

Mobocertinib succinate (TAK-788 succinate) inhibits all 14 mutant variants of EGFR (IC50s=2.4-22 nM), and all 6 mutant variants of HER2 (IC50s=2.4-26 nM), more potently than it inhibited WT EGFR (IC50=35 nM), including all 8 variants with exon 20 activating insertions[1].

In mice implanted with a patient-derived tumor containing an EGFR exon 20 activating insertion, or with engineered Ba/F3 cells containing a HER2 exon 20 activating insertion, once daily oral dosing of Mobocertinib succinate induced regression of tumors at doses that were well tolerated (30-100 mg/kg)[1].

[1]. Francois Gonzalvez, et al. Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models. April 16-20, 2016; New Orleans, LA.
[2]. Masood A, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on BIBW 2992. Semin Oncol. 2019 Jun;46(3):271-283.

Bewertungen

Review for Mobocertinib succinate

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Mobocertinib succinate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.